Nanomedicines Market
Global Nanomedicines Market Size, Share & Trends Analysis Report By Indication Type (Cardiovascular Diseases, Neurological Diseases, Infectious Diseases, Oncological Diseases, Orthopedic Diseases, and Other Diseases (Urological Disease, Ophthalmic Diseases)), and by Application (Drug Delivery, Active Implants, Vaccines, Diagnostic Imaging, Biomaterials, Regenerative Medicines, and Other Applications (Tissue Regeneration)) Forecast, 2021-2027 Update Available - Forecast 2024-2030
Nanomedicine plays a vital role in drug delivery and regenerative medicines. Nanoparticles enable the clinician to target drugs right at the root of disease, which not only increases efficiency but also minimizes side effects. They also offer new potential for the controlled release of therapeutic substances. The global nanomedicines market is projected to grow at a modest CAGR of 11.1% during the forecast period (2021-2027). The major aspect that drives the growth of the market includes the need for technological advancements to enhance disease diagnosis, treatment, and prevention. Nanomedicine offers promising changes from the current methods of diagnosing and treating various disorders. Nanomedicines are used for a wide range of applications such as resolving inflammation and develops tissue healing, treatment of cardiovascular diseases, neurological diseases, infectious diseases, oncological diseases, orthopedic diseases, and other diseases. An upsurge in the cases of such diseases is likely to create a wide scope for market growth during the forecast period.
However, the availability of various other drugs and treatment types is likely to challenge the growth of the market. Nevertheless, the continuous contributions by the key players in order to develop advanced and effective nanomedicines are likely to create lucrative opportunities for market growth during the forecast period.
Segmental Outlook
The global nanomedicines market is segmented on the basis of indication type and application. Based on the indication type, the market is segmented as cardiovascular diseases, neurological diseases, infectious diseases, oncological diseases, orthopedic diseases, and others. The other segment includes urological disease and ophthalmic diseases. Based on the applications, the market is segmented as drug delivery, active implants, vaccines, diagnostic imaging, biomaterials, regenerative medicines, and other applications. The other segment includes tissue regeneration.
Oncological Diseases Segment to Hold a Significant Market Share
Amongst the indication type segment of the global nanomedicines, the oncological diseases segment is projected to hold the most lucrative share in the market. The segmental growth of the market is accredited to the rising prevalence of cancer cases among people across the globe. As per the data extracted by the WHO (World Health Organization), the global cancer burden has risen to a whopping 18.1 million cases and more than 9 million fatalities in 2018. The report also stated that one in every 6 women and one in every 5 men develop cancer during their lifetime, with mortalities registered as one in 11 women and one in 8 men from cancer, globally. Further, metabolic syndrome is a cluster of conditions that occur together, increasing the risk of heart disease, stroke, and type-2 diabetes. These conditions include increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels, which prompts the demand for advanced medicines and in turn create scope for the market over the forecast period.
Global Nanomedicines Market, by Indication Type 2020 (%)
Regional Outlook
The global nanomedicines market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific region is projected to hold a significant market share. China, India, Japan, and the Rest of the Asia-Pacific are the major economies primarily contributing to the growth of the Nanomedicines market in the region. The regional growth of the market is accredited to the enhancing healthcare infrastructure in the emerging economies of the region such as India and China. The rising prevalence of various diseases such as cardiovascular diseases, neurological diseases, infectious diseases, oncological diseases, orthopedic diseases, and others, further creates scope for market growth over the forecast period.
Further, the North American region is also estimated to witness a significant value for the market, attributing to the presence of key players and research activities conducted by them across the region. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs for both commercial and public use was developed in the country under which companies are targeting the treatment of several cancer types and infectious diseases through various therapies, where nanoemulsion vaccines and drugs play a significant role.
Global Nanomedicines Market, by Region 2020 (%)
Market Players Outlook
The prominent players functioning in the global Nanomedicines market include 3M Co., Johnson & Johnson Services Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., AstraZeneca Plc., Celgene Corp., Pfizer Inc., Sanofi SA, and Smith & Nephew Plc among others. These key manufacturers are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, and many others in order to thrive in a competitive environment.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Nanomedicines market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. 3M Co.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Johnson & Johnson Services Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Merck & Co. Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Thermo Fisher Scientific Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Eli Lily & Co.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Nanomedicine Market by Indication Type
5.1.1. Cardiovascular Diseases
5.1.2. Neurological Diseases
5.1.3. Infectious Diseases
5.1.4. Oncological Diseases
5.1.5. Orthopedic Diseases
5.1.6. Other Diseases (Urological Disease, Ophthalmic Diseases)
5.2. Global Nanomedicine Market by Application
5.2.1. Drug Delivery
5.2.2. Active Implants
5.2.3. Vaccines
5.2.4. Diagnostic Imaging
5.2.5. Biomaterials
5.2.6. Regenerative Medicines
5.2.7. Other Applications (Tissue Regeneration)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. ASEAN
6.3.5. South Korea
6.3.6. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Affymetrix Inc.
7.2. AstraZeneca Plc.
7.3. Bristol-Myers Squibb Co.
7.4. Celgene Corp.
7.5. CytImmune Sciences Inc.
7.6. Ferro Corp.
7.7. GE Global Research
7.8. Gilead Sciences Inc.
7.9. Luminex Corp.
7.10. Nanobiotix SA
7.11. PerkinElmer Inc.
7.12. Pfizer Inc.
7.13. Sanofi SA
7.14. Shimadzu Co. Ltd
7.15. Smith & Nephew Plc
7.16. St. Jude Medical Inc.
7.17. Starpharma Holdings Ltd.
7.18. Stryker Corp.
7.19. Taiwan Liposome Co. Ltd.
7.20. UCB SA
1. GLOBAL NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
2. GLOBAL NANOMEDICINES FOR CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
3. GLOBAL NANOMEDICINES FOR NEUROLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL NANOMEDICINES FOR INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
5. GLOBAL NANOMEDICINES FOR ONCOLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL NANOMEDICINES FOR ORTHOPEDIC DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
7. GLOBAL NANOMEDICINES FOR OTHER DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
8. GLOBAL NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
9. GLOBAL NANOMEDICINES FOR DRUG DELIVERY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL NANOMEDICINES FOR ACTIVE IMPLANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL NANOMEDICINES FOR VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL NANOMEDICINES FOR DIAGNOSTIC IMAGING MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL NANOMEDICINES FOR BIOMATERIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL NANOMEDICINES FOR REGENERATIVE MEDICINES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL NANOMEDICINES FOR OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
16. GLOBAL NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
17. NORTH AMERICAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
18. NORTH AMERICAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
19. NORTH AMERICAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
20. EUROPEAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
21. EUROPEAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
22. EUROPEAN NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
23. ASIA-PACIFIC NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
24. ASIA-PACIFIC NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
25. ASIA-PACIFIC NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
26. REST OF THE WORLD NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY INDICATION TYPE, 2020-2027 ($ MILLION)
27. REST OF THE WORLD NANOMEDICINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
1. GLOBAL NANOMEDICINE MARKET SHARE BY INDICATION TYPE, 2020 VS 2027 (%)
2. GLOBAL NANOMEDICINE MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)
3. GLOBAL NANOMEDICINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
4. US NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
5. CANADA NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
6. UK NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
7. FRANCE NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
8. GERMANY NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
9. ITALY NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
10. SPAIN NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
11. ROE NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
12. INDIA NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
13. CHINA NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
14. JAPAN NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
15. ASEAN NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
16. SOUTH KOREA NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
17. REST OF ASIA-PACIFIC NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
18. REST OF THE WORLD NANOMEDICINE MARKET SIZE, 2020-2027 ($ MILLION)
